Spyre Therapeutics, Inc. (SYRE) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 7.37B USD. 52-week range 18.12 to 110.17 USD. Data as of 2026-10-09.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor ...